To further define the surface of the Torpedo californica nicotinic acetylcholine receptor (nAChR) contributing to the agonist binding site structure, we used the substituted Cys accessibility method to identify novel residues and determined the "footprint" of residues protected from modification by the reversible competitive antagonist d-tubocurarine (dTC). nAChRs containing single Cys substitutions within regions of the ␣-or ␥-subunit primary structure known to contribute to the agonist binding site were expressed in Xenopus laevis oocytes. Cys substitutions in binding site segments A (␣Tyr-93 and ␣Asn-94), C (␣Tyr-198), and D (␥Glu-57) had been shown previously to be accessible for modification. We now introduced cysteines from ␣Asp-195 to ␣Ile-201 and from ␥Ala-106 to ␥Asp-113 and identified positions accessible for modification in segments C ) and E (␥Asn-107 and ␥Leu-109). dTC protected against alkylation in segments D (␥Glu-57) and E (␥Leu-109) but not in segment A (␣Tyr-93 and ␣Asn-94). In segment C, dTC protection experiments revealed a pattern in which every other residue (␣196, ␣198, and ␣200, but not ␣197 or ␣201) was protected from alkylation. This pattern of protection provides evidence that bound dTC is near amino acids in segments C, D, and E but not in segment A, and identifies a ␤-strand surface within segment C contributing to the binding site. These results are discussed in terms of a homology model, based on the molluscan acetylcholine binding protein crystal structure, of the T. californica nAChR agonist binding site.
) and E (␥Asn-107 and ␥Leu-109). dTC protected against alkylation in segments D (␥Glu-57) and E (␥Leu-109) but not in segment A . In segment C, dTC protection experiments revealed a pattern in which every other residue (␣196, ␣198, and ␣200, but not ␣197 or ␣201) was protected from alkylation. This pattern of protection provides evidence that bound dTC is near amino acids in segments C, D, and E but not in segment A, and identifies a ␤-strand surface within segment C contributing to the binding site. These results are discussed in terms of a homology model, based on the molluscan acetylcholine binding protein crystal structure, of the T. californica nAChR agonist binding site.
The binding sites for agonists and competitive antagonists in the nicotinic acetylcholine receptor (nAChR) are within the extracellular domain at the ␣-␥ and ␣-␦ subunit interfaces. Affinity labeling and mutagenesis studies have provided extensive evidence for a model of the agonist site structure with contributing amino acids from three distinct regions of the ␣-subunits (referred to as binding site segments A, B, and C) and from at least three regions of the ␥ (or ␦)-subunit (segments D, E, and F) (reviewed in Prince and Sine, 1998; Arias, 2000; Corringer et al., 2000) . Most features of the model are present in the binding site identified within the recently solved structure of a molluscan, glial-derived soluble ACh binding protein (AChBP), a homopentameric structural and functional homolog of the N-terminal ligand binding domain of a nAChR ␣-subunit (Brejc et al., 2001; Smit et al., 2001) .
The substituted Cys accessibility method (Karlin and Akabas, 1998) has provided an alternative approach for characterizing structural features of the nAChR and other ion channels. An observed irreversible change in the functional properties of the channel, after exposure to a water-soluble sulfhydryl reagent, suggests that the substituted Cys is exposed at the water accessible protein surface. This technique has been used to identify the state-dependent accessibility of amino acids contributing to the ion conduction pathway of the nAChR (Akabas et al., 1994; Akabas and Karlin, 1995; Karlin, 1997, 1998) . In studies of the structure of the agonist binding site, which contains a disulfide bond between ␣Cys-192/193 in segment C, most Cys substitutions are well tolerated within ␣184 -198 and are accessible for modification (McLaughlin et al., 1995; Spura et al., 1999; Spura et al., 2000) . Using Cys mutagenesis of Torpedo californica nAChR, we previously tested the accessibility of positions identified by affinity labeling and mutagenesis in segments A (␣Tyr-93), B (␣Trp-149), C , and D (␥Trp-55 and ␥Glu-57) as well as surrounding amino acids in segments A (␣90 -96) and D (␥52-58) and found that , and ␥Glu-57 were accessible (Sullivan and Cohen, 2000) . That study also helped to define the structural requirements for ligand orientation compatible with nAChR activation, as [2-(trimethylammonium)-ethyl]-methanethiosulfonate (MTSET), which attaches thiocholine, acted as an irreversible antagonist at positions ␣Y93C and ␥E57C but as a covalent agonist at ␣Y198C. Furthermore, a structural analog with the tethering arm shortened by one methylene group (0.7 Å) acted as an irreversible antagonist at ␣Y198C and at all other accessible positions.
In this report, we extended these studies by identifying additional accessible residues in segment C (␣195-201) as well as segment E (␥106 -113), which includes residues identified by photoaffinity labeling with the antagonists [ 3 H]4-benzoylbenzoylcholine (␥Leu-109; Wang et al., 2000) and [ 3 H]d-tubocurarine (dTC) (␥Tyr-111; Chiara et al., 1999) . With these mutant nAChRs, we also tested whether MTSET or its analogs could act as irreversible agonists when tethered at positions other than ␣Y198C. In addition, we used the panel of nAChR binding site mutants containing accessible cysteines to identify positions that could be protected from alkylation when the agonist binding site was occupied by dTC. Based upon photoaffinity labeling, [
3 H]dTC binds to the agonist site at the ␣-␥ interface near amino acids in segments C , , and E (␥Tyr-111 and ␥Tyr-117; Chiara and Cohen, 1997; Chiara et al., 1999) , and dTC can protect against MTSET reaction at ␣Y198C (Sullivan and Cohen, 2000) . The results we now report, which indicate protection of alkylation of positions in segments C, D, and E but not in segment A, are consistent with the results of photoaffinity labeling. The pattern of protected residues within segment C indicates that this region is organized as a ␤-strand and identifies a surface projecting toward the ACh binding site consistent with the structure of the binding site in the AChBP (Brejc et al., 2001 ). However, the lack of protection of ␣Y93C is surprising in terms of that structure. Our experimental results are compared with a homology model of the T. californica agonist binding site based on the crystal structure of the AChBP and are generally consistent with this structure. However, the accessibility of some residues suggests differences between the model and the structure of the T. californica nAChR binding site in the absence of agonist (our experimental conditions).
Materials and Methods
cDNA Mutagenesis. Mutants were constructed by "overlap extension" PCR using T. californica nAChR subunit plasmids (␣, ␥, and ␦ in pMXT and ␤ in pSP64) and reagents as described previously (Sullivan and Cohen, 2000) . The mutations of amino acids 195-201 of the mature ␣-subunit were generated using primers which gave a PCR product of ϳ1000 base pairs that could be subcloned using the unique BsiWI restriction site and the BbvII site near the 3Ј end of the ␣-subunit coding region. Mutations of amino acids 106 to 113 in the mature ␥-subunit were made by generating a PCR product of ϳ1.13 kilobases that was subcloned using the unique HindIII site in the vector and the StuI site in the ␥-subunit coding region. Each PCR mix contained 0.5 M primers, 50 ng of template DNA, and 0.4 mM dNTPs in the reaction buffer supplied with the enzyme. PCR reactions were for 24 cycles with a threestep protocol (1.5 min at 95°C, 45°C, and 72°C).
Electrophysiology. T. californica nAChR subunit-specific cRNAs were transcribed in vitro and Xenopus laevis oocytes were injected as described previously (Sullivan and Cohen, 2000) . Isolated, follicle-free oocytes were injected with 0.5 to 10 ng of subunitspecific RNAs in a molar ratio of 2␣/␤/␥/␦, and currents elicited by ACh were measured 48 to 72 h after injection by two-electrode voltage clamp. Under our experimental conditions, for oocytes injected with 0.5 ng of wild-type nAChR subunit cRNAs, maximal current responses for ACh were typically 1 to 2 A. For the Cys substitutions between ␣195 and ␣201 in segment C, the maximal current responses for ACh were similar to wild-type for the mutant nAChRs containing Cys at ␣195, ␣196, ␣197, or ␣199. As described previously, the ␣Y198C nAChRs showed maximal current levels ϳ1% of wild-type, and for the ␣D200C and ␣I201C mutant nAChRs, the maximal currents were also 1 to 5% of wild-type. For ␣Y198C, as judged by binding of 125 I-␣-bungarotoxin to intact oocytes, surface nAChR levels were ϳ50% of wild-type. Within segment E (␥106-113), the maximal ACh current responses were similar to wild-type for each substitution except for ␥Y111C, which had maximal responses ϳ2% of wild-type and surface nAChR levels Ͻ10% of wildtype. Surface receptor expression levels of other mutants were not quantified. Salts, atropine, ACh, and dTC were from Sigma (St. Louis, MO). MTSET, [3-(trimethylammonium)-propyl]-methanethiosulfonate (MTSPT), 2-aminoethylmethanethiosulfonate (MTSEA), and 4-(N-maleimido)benzyltrimethylammonium (MBTA) were from Toronto Research Chemicals (North York, Ontario, Canada), and Biotin-PEO-maleimide ( Fig. 1 ) was from Pierce (Rockford, IL). Sulfhydryl-modifying reagents were prepared as millimolar stock solutions in recording solution and stored on ice during use, with fresh solutions prepared approximately every 2 h. For nAChR activation, ACh dose response curves were fit to the equation:
, where I and I max are the currents at a given concentration of ACh and the maximal current, respectively. K app is the apparent activation constant for ACh and n H is the Hill coefficient. pCLAMP (Axon Instruments, Foster City, CA) and SigmaPlot (SPSS Inc., Chicago, IL) software were used for data analysis.
Rate Constants of nAChR Modification. For the sulfhydrylreactive reagents producing irreversible inhibition of ACh responses, the time course of the reaction with a substituted Cys mutant in the absence of ACh was determined by recording the initial response to ACh and then the response to ACh after repeated applications of modifying reagent for 5-s intervals. Each application of reagent was followed by a ϳ1-min wash, three ACh test applications (5 s each), and a 1-min wash. ACh was generally applied at a concentration equal to K app . ACh-induced currents after treatment were plotted as a function of cumulative modification time (t) and fit by a single exponential function, I t ϭ I ϱ ϩ (I o Ϫ I ϱ ) exp(Ϫt / ) where I t is the current at a given time, I ϱ is the amount of current remaining after the reaction is complete, and I o is the initial current level. 1 / is the pseudo-first-order rate constant and the second-order rate constant, k, is (1 / ) / x, where x is the concentration of modifying reagent.
dTC Protection Assay. Responses to ACh at a concentration near K app were measured before and after coapplication of dTC and ACh to show that 10 M dTC was sufficient to reversibly block Ͼ95% of the ACh response and that the Cys substitution itself had not interfered with the receptors' ability to bind dTC. This initial part of the assay was also necessary to determine that the effects of dTC were reversible. It was often necessary to wash the oocyte for several minutes after dTC application for full recovery of the ACh response. To measure the degree of protection by dTC, ACh test pulses were measured before and after 10 M dTC was coapplied with a concentration of MTSET known to cause 50 to 80% inhibition (based on rate constants). The same concentration of MTSET was then applied in the absence of dTC, again using ACh test pulses to measure the extent of inhibition. The degree of protection was then determined by comparing the ratio of the extent of modification in the absence of dTC to the extent of modification in the presence of dTC:
Homology Modeling of the T. californica nAChR. Molecular modeling of the extracellular domain of the T. californica nAChR based upon the recently published structure of the AChBP (Brejc et al., 2001 ) was done using Insight II (Version 98; MSI, San Diego, CA) on a Silicon Graphics O 2 workstation. The sequences for the four T. californica nAChR subunits (NCB accession numbers: ACRYA1, ACRYB1, ACRYG1, and ACRYD1) were obtained from the National Center for Biotechnology Information and the coordinates for the structure of the AChBP (PDB number 1I9B) were obtained from the Research Collaboratory for Structural Bioinformatics (http://www.rcsb.org). The nAChR subunit sequence alignment presented by Brejc et al. (2001) was used, and the AChBP structure was examined to ensure that insertions and deletions occurred within exposed flexible segments. The Insight II Homology module placed the nAChR sequences into the AChBP structure and the Insight II Discovery module energy minimized the resulting structural model. Compared with the primary structure of the AChBP, the nAChR ␣-subunit contains insertions in two regions within the ACh binding site. Although segment C in all neuronal nAChR ␣-subunits aligns well with the AChBP, the T. californica and skeletal muscle ␣-subunits contain a single residue insertion between ␣Cys-193 and ␣Tyr-198. We designated ␣Asp-195 as the inserted residue to preserve the ␤10-strand beginning at projecting in the direction of the binding site, a structure consistent with experimental results described in this report. The other ␣-subunit insertion in the vicinity of the binding site was ␣Ala-96 in segment A. Both insertions were well tolerated upon minimization.
The only region of nAChR subunit primary structure which was not a straightforward substitution or small segment insertion was the poorly aligned region encompassing the amino acids of binding site segment F. This region of primary structure required insertions of 9, 7, and 11 amino acids in the ␤-, ␥-, and ␦-subunits, respectively, in the segment region between the ␤8 and ␤9 ␤-strands. Lacking additional guidelines, we placed these insertions (␤164-172, ␥164-170, and ␦166-176) in external loops to preserve the structure of the adjacent regions that were homologous to the AChBP sequence. In our model, ␥Ser-161, which has been identified as a dTC selectivity determinant for mouse nAChR (Sine, 1993) , occurs just after the ␤8-strand and is positioned beyond ␥Lys-34, ϳ15 Å from the center of the aromatic binding pocket. Similarly, ␥Glu-183, which was identified as a determinant of agonist K app (Czajkowski et al., 1993) , occurs at the NH 2 terminus of the ␤9-strand, which would lie near the plane of the membrane in a nAChR, 26 Å from the agonist binding site. ␥Asp-177 is positioned outside of ␣Tyr-190/␥Trp-55, closer to the binding pocket than ␥Asp-174, an important determinant of agonist K app (Martin et al., 1996; Martin and Karlin, 1997) . Because segment F residues seem more distantly related to the core structure of the binding site and amino acids in this region have not been examined in this study, the predicted positions of these residues are not included in our model of the T. californica nAChR ACh binding site.
In the AChBP structure, a HEPES molecule was identified within the aromatic pocket of the ACh binding site. We placed ACh molecules into the equivalent positions of our nAChR model (at the ␣-␥ and ␣-␦ interfaces) using the Insight II Docking module, and the structure containing the ACh molecules was energy minimized. A single orientation for each ACh molecule was favored (docking energy of Ϫ30 kcal), which placed the ACh nitrogen within the aromatic pocket of the ligand binding site consisting of , and ␥Trp-55/␦Trp-57.
Results
Functional Properties of nAChRs with Cys Substitutions in Binding Site Segments C and E. nAChR functional properties were assessed by measuring ACh-elicited currents using two-electrode voltage clamp. Each of the substitutions within ␣195-␣201 and ␥106-␥113, when expressed with other wild-type subunits, resulted in functional nAChRs (Table 1) . For wild-type nAChR, the K app for ACh was 30 Ϯ 8 M. For the segment C mutant nAChRs, there was a significant rightward shift of K app only for the Cys substitution at ␣Y198C. The mutant nAChRs with substituted Cys adjacent to ␣Tyr-198 at either ␣Pro-197 or ␣Leu-199 were characterized by leftward shifts of K app , whereas for the other substitutions studied in this segment, the K app values were shifted Ͻ2-fold compared with wild-type. The Cys substitutions in segment E (␥106-␥113) were also well tolerated. The largest shifts of K app were seen for the ␥L109C (K app ϭ 100 M) and ␥Y111C (K app ϭ 14 M) mutants, whereas for substitutions at each of the other positions, K app for ACh was within a factor of 2 of wild-type.
Modification of Substituted Cysteines within Binding Site Segment C. For oocytes expressing wild-type or mutant nAChRs, the response to ACh was measured at a concentration close to K app . Oocytes were then exposed to MTSET (200 M), MTSEA (1 mM), or maleimide-PEO-biotin TABLE 1 Functional properties of binding site segment C and E mutant nAChRs Macroscopic dose response curves were measured as described under Materials and Methods with the tabulated K app representing the mean Ϯ S.D. determined from at least three oocytes. For wild-type nAChR, n H ϭ 1.6 Ϯ 0.1, and the Hill coefficients for the Cys mutants, measured in the same manner, were not significantly different from wild-type. (1 mM) ( Fig. 1) for 5 s in the absence of agonist; after a wash of 1 to 2 min, the ACh response was remeasured. Representative current traces are shown for wild-type and segment C mutant nAChRs treated with MTSET ( Fig. 2A) , and summary data for each of the mutants are presented for the effects of MTSET, MTSEA, and maleimide-PEO-biotin (Fig.  2B ). We were particularly interested in determining whether thiocholine tethered at positions other than ␣Y198C in segment C would result in covalent activation. However, treatment with MTSET for 5 s resulted in irreversible inhibition of the ACh response by Ͼ75% for the ␣T196C, ␣P197C, and ␣D200C mutant nAChRs, and a smaller inhibition of the ␣I201C mutant that increased with longer reaction times (see later). The ϳ10% inhibition of the ␣D195C or ␣L199C mutants was less than that seen for wild-type nAChR and was not indicative of modification of the substituted Cys. Treatment with MTSEA also resulted in irreversible inhibition of ACh current responses for those mutants sensitive to MTSET. Modification with maleimide-PEO-biotin (1 mM, 5 s) significantly inhibited the ACh responses for the same mutants and, in addition, it inhibited irreversibly the ␣D195C nAChR mutant.
To look further for the possibility of channel activation, we also tested the effects of MTSPT, which is one methylene group longer than MTSET, reasoning that the quaternary ammonium attached to a longer tethering arm might act as an agonist if attached at other positions in proximity to ␣Tyr-198 (data not shown). MTSPT confirmed the accessibility of residues ␣T196C, ␣P197C, and ␣D200C by inhibiting subsequent ACh responses, but it only activated the ␣Y198C mutant, as described previously (Sullivan and Cohen, 2000) .
Modification of Substituted Cysteines within Binding Site Segment E. Cys substitutions at ␥106 to ␥113 were similarly tested for their sensitivity to MTSET and MTSEA (Fig. 3) . Summary data show that a 5-sec exposure to MTSET (200 M) or MTSEA (1 mM) inhibited ACh responses for the ␥N107C mutant by ϳ30 and 75%, respectively, whereas both compounds inhibited the ␥L109C response by ϳ90%. Effects at the other positions tested were not sufficiently different from wild-type to make any conclusions about their accessibility. Exposure of these mutants to maleimide-PEO-biotin did not yield any additional information about residue accessibility (data not shown).
Reaction Rate Constants. The rates of reaction were measured to determine the effect of full modification at a particular residue in response to a specific reagent and to give us the kinetic information necessary to design protocols for subsequent dTC protection experiments. For the Cys mutants inhibited irreversibly by MTSET or MTSEA, the rates of reaction with mutant nAChRs were determined by measuring the response to ACh after increasing reaction times and for various reagent concentrations (Fig. 4) . For oocytes expressing ␣Y93C, ␣Y198C, and ␥E57C nAChRs, ACh responses were inhibited by Ͼ90% after full modification (Sullivan and Cohen, 2000) . In contrast, even after complete modification, the ACh current response was not fully inhibited for a number of the segment C and E Cys mutants characterized here. For ␣T196C and ␣I201C mutant nAChRs, ACh current responses were maximally inhibited 30 to 50% by MTSEA, whereas ␣P197C and ␣D200C responses were inhibited by 75% and 95%, respectively (Fig.  4A ). For substitutions in segment E, MTSEA treatment inhibited ␥N107C responses by 80%, whereas it inhibited ␥L109C responses by Ͼ90% (Fig. 4B) , similar to the level of inhibition seen for the ␥E57C mutant. MTSET treatment of ␣T196C nAChRs resulted in maximal inhibition of 80% (Fig.  4C) , compared with the maximal inhibition of 30% seen after reaction with MTSEA. MTSET also more fully inhibited responses at ␣P197C than MTSEA. MTSET treatment inhibited to the same extent as MTSEA at ␣D200C (Ͼ90%) and ␣I201C (50%). For substitutions in the ␥-subunit, MTSET fully inhibited the ␥E57C and ␥L109C nAChR, whereas for the ␥N107C nAChR, maximal inhibition was only 50% (Fig.  4D) .
We also examined the kinetics of modification of the mutant nAChRs by MBTA (Fig. 1) , the alkylating antagonist used (Kao et al., 1984) to identify ␣Cys-192/193 as amino acids of the agonist binding site in the T. californica nAChR (after disulfide reduction). Reaction with MBTA at ␣T196C, ␣P197C, ␣D200C, and ␥L109C resulted in irreversible inhibition of the ACh responses to the same extent as seen after modification with MTSET (Fig. 4, E and F ). ␣I201C and ␥N107C (Fig. 4 , E and F) nAChRs, although sensitive to MTSEA and MTSET, were not inhibited after exposure to MBTA, suggesting that MBTA modification may be more orientation-dependent.
The apparent bimolecular reaction rate constants for MTSEA, MTSET, or MBTA modification of the mutant nAChRs (Table 2) were determined from the rates of reaction, which increased with increasing reagent concentration. While the reaction rate constants at ␣Y93C, ␣Y198C, and ACh responses were measured before and after each 5-s application of reagent and were normalized to the initial response. Plots were fit with single exponential functions as described under Materials and Methods to give the first-order rate constant 1/ (s Ϫ1 ) and the fractional response remaining after full modification, I ϱ . A, MTSEA modification rates are shown for segment C residues: ␣T196C, 1 mM ( ϭ 6 s, I ϱ ϭ 0.65); ␣P197C, 30 M ( ϭ 6 s, I ϱ ϭ 0.26); ␣D200C, 100 M ( ϭ 13 s, I ϱ ϭ 0.06); ␣I201C, 1 mM ( ϭ 8 s, I ϱ ϭ 0.56). B, MTSEA modification rates are shown for ␥-subunit Cys substitutions in binding site segments D and E: ␥E57C, 300 M ( ϭ 10 s, I ϱ ϭ 0); ␥N107C, 30 M ( ϭ 8 s, I ϱ ϭ 0.13); ␥L109C, 30 M ( ϭ 5 s, I ϱ ϭ 0.09). C, MTSET modification rates are shown for segment C residues: ␣T196C, 300 nM ( ϭ 10 s, I ϱ ϭ 0.18); ␣P197C, 30 M ( ϭ 6 s, I ϱ ϭ 0.08); ␣D200C, 100 M ( ϭ 12 s, I ϱ ϭ 0.06); ␣I201C, 1 mM ( ϭ 7 s, I ϱ ϭ 0.37). D, MTSET modification rates for ␥-subunit: ␥E57C, 100 M ( ϭ 8 s, I ϱ ϭ 0.07); ␥N107C, 100 M ( ϭ 22 s, I ϱ ϭ 0.18); ␥L109C, 10 M ( ϭ 5 s, I ϱ ϭ 0.09). E, MBTA modification rates are shown for segment C residues: ␣T196C, 150 nM ( ϭ 6 s, I ϱ ϭ 0.36); ␣P197C, 100 M ( ϭ 26 s, I ϱ ϭ 0.03); ␣D200C, 3 M ( ϭ 11 s, I ϱ ϭ 0); ␣I201C, 1 mM (not fit). F, MBTA modification rates for ␥-subunit segment D and E residues: ␥E57C, 100 M ( ϭ 12 s, I ϱ ϭ 0); ␥N107C, 1 mM (not fit); ␥L109C, 3 M ( ϭ 17 s, I ϱ ϭ 0.15). Parameter uncertainties were 5 to 20% for and 1 to 15% for Iϱ. ␥E57C differed by as much as 500-fold, at each position, the rate constants for MTSEA and MTSET differed by Ͻ2-fold, and the rate constants for MBTA were never larger than for MTSET. For the other positions tested within segment C, the rate constants for MTSET (or MTSEA) varied by ϳ100-fold without any characteristic periodicity, and the rate constants for MBTA varied by as much as 3000-fold at adjacent amino acids (␣T196C, ␣P197C). At ␣T196C, MTSET (k ϳ 2 ϫ 10 5 M Ϫ1 s Ϫ1 ) reacted ϳ1000-fold faster than MTSEA, whereas at the other positions examined, the rate constants for the two compounds differed by Ͻ2-fold. Whereas the rate constant for MBTA reaction with ␣Y198C (k ϳ 5 ϫ 10 3 M Ϫ1 s Ϫ1 ) was only 2% of that for MTSET, for ␣T196C the rate constant for MBTA (k ϳ 1 ϫ 10 6 M Ϫ1 s Ϫ1 ) was 5-fold higher than that for MTSET and similar to the rate constant for MBTA modification of ␣Cys-192/193 in reduced, native T. californica nAChR (k ϳ 3 ϫ 10 6 M Ϫ1 s Ϫ1 ) (Stauffer and Karlin, 1994) . At ␣D200C the rate constant for MBTA (k ϳ 5 ϫ 10 4 M Ϫ1 s Ϫ1 ) was 50-fold higher than for MTSET. Within segment E, the rate constant for MTSET reaction at ␥L109C (k ϳ 2 ϫ 10 4 M Ϫ1 s Ϫ1 ) was 40-fold greater than at ␥N107C, and for ␥L109C or ␥E57C nAChRs the rate constants for MTSEA, MTSET and MBTA were essentially the same.
Effects of Alkylation on ACh Dose Response. Analysis of the kinetics of MTSET modification of the mutant nAChRs revealed that after full modification, ACh responses were inhibited by Ն90% at some positions (␣Y93C, ␣P197C, ␣D200C, ␥E57C, ␥L109C) but not at others (␣T196C, ␣I201C). For the latter positions, it was clear that the tethered thiocholine modified the ACh response but did not prevent ACh binding. Additional experiments were carried out to determine whether, at the other positions, tethered thiocholine acted as an irreversible antagonist or alternately as a modifier of ACh binding and/or gating. We characterized ACh dose response curves before and after modification to determine whether the inhibition seen at a fixed concentration of ACh resulted from reduction only of the maximal response or also from a modification of K app . If modification resulted in a nAChR no longer capable of being activated by ACh, then any ACh induced currents could result only from remaining unmodified nAChRs, and the response after exposure to MTSET would be characterized by a decreased maximal current without change of K app . For example, modification of ␣Y93C or ␥E57C nAChRs by MTSET or MTSEA resulted in reductions of maximum current without change of K app (Sullivan and Cohen, 2000) . If after modification, ACh was still able to gate the ion channel, but with either the binding or gating altered, then the response could be characterized by a shift of K app .
For the two positions apparently insensitive to MTSET (␣D195C and ␣L199C), the shifts of the ACh dose response curves after MTSET treatment (ϳ20% reduction of maximal response, K app shift Ͻ1.5-fold) were similar to the effects of MTSET on wild-type nAChR (Fig. 5, A and B ; data not shown). For two positions with substantial responses after full modification (␣T196C and ␣I201C), K app values were shifted by Ͻ2-fold (Fig. 5, A and C) . The ␣P197C nAChR was inhibited by Ͼ90% when tested at 30 M ACh (Fig. 4C ). This inhibition resulted from a 10-fold increase in K app with less than a 20% reduction of the maximal response (Fig. 5B) . After full modification of the ␣D200C mutant, the maximal response was reduced by only 80% and the K app value increased 2-fold (Fig. 5C) . Thiocholine tethered at ␣T196C, ␣P197C, ␣D200C, or ␣I201C altered either ACh binding or gating, but did not act as a covalent antagonist that prevented the binding of ACh.
For substitutions in the ␥-subunit, modification of either ␥E57C or ␥L109C can cause Ͼ90% inhibition of the ACh response when tested at a concentration near K app (Fig. 4D) . For the ␥E57C mutant, limited modification of nAChRs by exposure to 100 M MTSET for 5 s resulted in a 70% reduction of maximal response with no shift of K app (Fig. 5D) . Treatment of the ␥L109C mutant with 200 M MTSET for 5 s, which was sufficient for maximal modification (Fig. 4D) , resulted in a reduction of the maximum response by only 70% accompanied by a 3-to 4-fold increase in K app (Fig. 5D ). Thus, with thiocholine tethered at ␥L109C, ACh was still able to bind and gate the ion channel.
dTC Protection Experiments. From our previous work and the experiments presented here, we identified accessible residues in ACh binding site segments A (␣Y93C and ␣N94C), C (␣D195C, ␣T196C, ␣P197C, ␣Y198C, ␣D200C, and ␣I201C), D (␥E57C), and E (␥N107C and ␥L109C). However, the fact that modification of the substituted cysteines led to altered ACh responses does not establish that these positions actually contribute to the structure of the ACh binding site. The altered responses could result from an allosteric modification of the structure of the binding site or from a perturbation of the conformational transition necessary for channel gating. If MTSET is within the agonist binding site when it reacts with a substituted Cys, then that reaction should be inhibited by the presence of a reversible agonist or antagonist that is bound in proximity to that position.
We used the competitive antagonist dTC to initially characterize the effects of cholinergic drugs on the modification by MTSET. When applied with an ACh concentration causing ϳ50% maximal response, we found that 10 M dTC was sufficient to block Ͼ95% of the ACh responses for the wild-type and the Cys mutant nAChRs, with Ͼ90% recovery from inhibition when the ACh response was retested after a wash of 1 to 2 min (data not shown). To measure the degree of protection by dTC, ACh test pulses were determined before and after 10 M dTC was coapplied for 5 s with a concentration of MTSET known to cause 50 to 80% inhibition. The same concentration of MTSET was then applied for 5 s in the absence of dTC, again using ACh test pulses to measure the extent of inhibition.
Representative current traces for dTC protection experiments are shown for residues in segments A, D, and E (Fig.  6 , left) and for segment C (Fig. 6, right) . ACh responses for wild-type nAChRs did not change after dTC/MTSET or MTSET application. dTC at 10 M did not prevent reaction of MTSET at residue ␣Y93C. ␣Y93C nAChRs were inhibited by ϳ90% when MTSET was applied in the presence of dTC, and the remaining ACh response was inhibited by a further treatment by MTSET alone. Similarly, dTC did not prevent reaction of MTSET with ␣N94C (not shown). In contrast, for ␥E57C in segment D, ␥L109C in segment E, and for some of the positions in segment C, dTC did protect against modification by MTSET. dTC provided 90% protection of the ␥E57C and ␥L109C nAChRs. For example, for ␥E57C, the ACh response was inhibited by only 7% after the oocyte was perfused with MTSET in the presence of dTC and then inhibited by 75% after perfusion with MT-SET alone.
Similar protection experiments were done for the segment C residues accessible to MTSET modification (Fig. 6, right) .
Because of the high reaction rate constant for MTSET modification of ␣T196C, MTSET was used at 1 M for that position. Consistent with lower rate constants for modification of the other positions (Table 2) , MTSET was tested at 10 M for ␣P197C, at 100 M for ␣D200C, and at 1 mM for ␣I201C. dTC protected against MTSET modification at ␣T196C and ␣D200C but not at ␣P197C and ␣I201C. For the ␣T196C receptor, dTC protected by ϳ80% in the experiment shown in Fig. 6 ; in two additional experiments, dTC protected ␣T196C by ϳ60%. For the ␣D200C receptor in the experiment shown (Fig. 6 ) and in an additional experiment, dTC protected by 80 to 90%. dTC did not protect the ␣P197C nAChR from modification: there was ϳ40% inhibition of the ACh response after treatment with MTSET in the presence or absence of dTC. Similarily, dTC did not protect the ␣I201C nAChR from modification. Exposure to 1 mM MTSET for 5 s in the presence of dTC caused ϳ20% inhibition of the subsequent ␣I201C ACh response, whereas application of 1 mM MTSET alone caused only a further 10% inhibition of the ACh response. Because there was more inhibition after exposure to MTSET in the presence of dTC than in its absence, we conclude that dTC afforded no protection at ␣I201C. Thus, within segment C, dTC binding protected against alkylation at ␣T196C, ␣Y198C (previously shown), and ␣D200C, but not at ␣P197C or ␣I201C.
A Homology Model of the T. californica nAChR Binding Site. The studies described above were carried out before the publication of the structure of the molluscan AChBP (Brejc et al., 2001) . To facilitate discussion of our results, we developed a model of the T. californica nAChR ␣-␥ binding site based upon the structure of the AChBP (Fig. 7) . The amino acids identified by affinity labeling and mutagenesis as contributors to the ACh binding site of the nAChR are located at each subunit interface, with amino acids of segments A, B, and C contributed from one subunit and amino acids from segments D, E, and F from the other. Secondary structure elements are identified by the ribbon representation and key binding site side chains depicted in ball and stick representation. After energy minimization of the AChBP model backbone containing the primary sequences of the extracellular regions of the T. californica nAChR subunits, no significant movement was noted for the structures containing the amino acids of binding site segments A-E. As discussed in "Materials and Methods", the size of the insertions in the segment F region of the ␥-or ␦-subunit prohibits any confident prediction of the position of those insertions, and we do not depict amino acids from this region in our model of the binding site. With that caveat, the most prominent structure changes between the ACh binding site of the AChBP and the model of the T. californica nAChR binding site were due to single amino acid substitutions, primarily within segment E.
The binding site is a pocket lined by aromatic side chains from ␣Tyr-93, , and ␥Trp-55. ␣Tyr-93 and ␣Trp-149 are positioned in segments immediately after ␤-strands (AChBP ␤4 and ␤7, respectively). ␣Tyr-190 and ␣Tyr-198 are on the same side of antiparallel ␤-strands (AChBP ␤9 and ␤10) with the turn formed by the ␣Cys-192/193 disulfide, which also contributes to the top of the binding pocket. The side chains of the amino acids identified from ␥-subunit segments E (␥Leu-109, ␥Tyr-111, ␥Tyr-117, and ␥Leu-119) and D (␥Trp-55, ␥Glu-57) are on a com- Fig. 6 . Competitive antagonist protection of MTSET alkylation of reactive Cys residues. To measure the degree of protection by 10 M dTC, current responses to ACh at a concentration near K app were measured before and after 10 M dTC was coapplied for 5 s with a concentration of MTSET known to cause 50 to 80% inhibition. The same concentration of MTSET was then applied for 5 s in the absence of dTC, again using ACh test pulses to measure the extent of inhibition. The degree of protection was defined as [1 Ϫ (% Inhibition dTC/MTSET / % Inhibition MTSET )] ϫ 100. Current traces are shown from oocytes expressing wild-type and nAChRs with substitutions in segments A (␣Y93C), D (␥E57C), and E (␥L109C) (left) and segment C (␣T196C, ␣P197C, ␣D200C, and ␣I201C) (right). Horizontal scale bar is 5 s.
nAChR Agonist Binding Site Structure 469 mon surface of three adjacent ␤-strands (AChBP ␤5Ј, ␤6, ␤2) which form a ␤ sheet extending to ␤1 that includes ␥Lys-34, an affinity determinant for agonists (Prince and Sine, 1996) and for ␣-conotoxin M1, a peptide antagonist (Sine et al., 1995; Bren and Sine, 2000) . As predicted from the results of affinity labeling and mutagenesis (Chiara et al., 1999; LeNovere et al., 1999) , the segment E amino acids are on antiparallel ␤ strands with a three-amino-acid turn centered on ␥Asp-113. Whereas ␥Trp-55 contributes to the base of the pocket, the side chains of ␥Leu-109, ␥Tyr-111, and ␥Tyr-117 form part of the entrance to the pocket. ␥Leu-119, a position identified by Cys mutagenesis of mouse nAChR as important for ␣-bungarotoxin binding (Sine, 1997; Osaka et al., 2000) , is the side chain from segment E that projects closest to the aromatic side chains forming the binding pocket, and the turn at ␥Asp-113 is most distant (ϳ20 Å) from the aromatic pocket. While the positions of segment F agonist/antagonist affinity determinants are not included in Fig. 7 , their distances from the center of the aromatic binding pocket are described in Materials and Methods.
The subunit primary structure of the AChBP is most closely related to the extracellular domain of nAChR ␣-subunits; as a homopentamer, it is more similar in structure to the ␣7 homopentameric neuronal nAChR than to the muscletype nAChR. It has yet to be determined whether the AChBP undergoes conformational changes analogous to those seen with the nAChR. Because the AChBP binds ACh with reasonably high affinity (K ϭ 4 M) , it is plausible that its binding site structure differs from that of the nAChR in the resting (closed channel) state, which has low affinity for agonist, and is more similar to that of the nAChR in either the desensitized or open channel states, which bind ACh with high affinity.
Discussion
In this study, we have determined the accessibility for modification of individually substituted cysteines within segments C (␣195-201) and E (␥106 -113) and have further assessed their accessibility in the presence of the competitive antagonist dTC. We previously identified ␣Y93C, ␣N94C, ␣Y198C, and ␥E57C as accessible for modification (Sullivan and Cohen, 2000) . Similar to the results obtained for segments A and D, within segment E, only two positions (␥N107C, ␥L109C) were clearly identified by our assay as accessible for modification. Within segment C, all of the positions tested demonstrated accessibility for modification, except for ␣L199C. The pattern of protection by dTC identifies residues within the binding site likely to be in close proximity to bound dTC, and the selective protection of residues within segment C identifies the surface of a ␤-strand projecting into the dTC/agonist binding site. With the availability of a model of the T. californica nAChR extracellular domain, based upon the AChBP structure, it becomes possible to evaluate our results to identify consistencies and differences between the model and the structure of the nAChR binding site in the absence of agonist.
Modification of Substituted Cysteines within Segments C and E. Our studies in segment C complement previous studies in which functional embryonic mouse Cys mutant nAChRs (␣183-197) were expressed on the cell surface and accessible for modification by a thiol-specific biotin, with the exception of ␣Y190C (Spura et al., 2000) . We found that ACh responses were readily quantified for each mutant T. californica nAChR containing Cys substitutions within ␣195-201, and all residues within ␣195-201, with the exception of ␣L199C, were accessible for modification. For most of these positions, introduction of either a primary amine (after MTSEA reaction) or quaternary amine (after MTSET or MBTA reaction) caused an altered response to ACh rather than an irreversible inhibition of binding. For the ␣Y93C, ␥E57C, and ␣Y198C receptors, earlier results indicated that covalent modification prevented the binding of ACh. Clearly, direct radioligand binding studies are required to determine the equilibrium constants for ACh binding to the modified Cys mutant nAChRs.
For the Cys substitutions within ␥106-113 of segment E, ACh responses were modified after MTSEA or MTSET reaction with ␥N107C and ␥L109C. Reaction of the ␥Y111C nAChR with any of the reagents had no effect on ACh responses. This was surprising, because ␥Tyr-111 is photola- Fig. 7 . Stereo representation of the T. californica nAChR agonist binding site at the interface between the ␣-and ␥-subunits. A homology model of the T. californica nAChR was constructed from the known three-dimensional structure of the molluscan AChBP. The ␤-sheet regions of the model are denoted by the numbering system for the AChBP (␤1, ␤2, etc.). A stereo representation of the ACh binding site is presented in ball and stick representation of side chains identified by affinity labeling or mutational analyses, including the Cys substitutions described in this report. The amino acids identified are in binding site segments A (␣Tyr-93 and ␣Asn-94, gold), B (␣Trp-149 and ␣Tyr-151, red), C blue] , D (␥Trp-55 and ␥Glu-57, green), and E (␥Asn-107, ␥Leu-109, ␥Tyr-111, ␥Tyr-117, and ␥Leu-119, magenta). A section of the segment F ribbon is included (gray) as well as ␥Lys-34 on ␤1 (brown). An ACh molecule (dotted Connolly surface) is shown within the site. After energy minimization, the ACh nitrogen, represented by the cyan sphere, is equidistant (ϳ5 Å) from the aromatic side chains of ␥Trp-55, ␣Trp-149, ␣Tyr-190, and ␣Tyr-198 and 6 Å from ␣Tyr-93. The acetyl group protrudes into the opening between segments C and E with the carbonyl oxygen oriented toward ␥Leu-119. The arrow denotes the likely route of ligand access. (Chiara et al., 1999) . However, substitution of ␥Tyr-111 by arginine had no effect on ACh equilibrium binding affinity or on the concentration dependence of channel activation, and it is quite likely that MTSET (or MBTA) may have reacted with ␥Y111C without altering the ACh response.
dTC Protection and Binding Site Structure. Because our functional assay identified modification of substituted cysteines in segments A (␣Y93C, ␣N94C), C (␣196-201, except ␣L199C), D (␥E57C), and E (␥N107C, ␥L109C), we wanted to determine how dTC binding altered the accessibility of cysteines for modification. If bound dTC sterically occluded access of MTSET to a binding site Cys, the rate of reaction would be reduced in proportion to dTC occupancy. Within segment C, dTC protected substituted cysteines from alkylation at ␣196, ␣198, and ␣200 but it did not protect ␣197 or ␣201. This dTC protection pattern is readily explained if this portion of segment C were organized as a ␤-strand with the side chains of ␣196, ␣198, and ␣200 on a common surface projecting toward the dTC/ACh binding site, as is seen in the structure of the molluscan AChBP (Brejc et al., 2001 ) and in the nAChR binding site model (Fig. 7, blue) .
The fact that dTC protects ␣Y198C, ␥E57C, and ␥L109C from modification but not ␣Y93C or ␣N94C is consistent with the results of [ 3 H]dTC photolabeling, where there was no detectable incorporation of [ 3 H]dTC into ␣Tyr-93 but there was photoincorporation into ␣Tyr-198, ␥Trp-55, and ␥Tyr-111. In addition, substitutions at ␣Tyr-93 did not alter dTC affinity (Sine et al., 1994) . However, within the AChBP and T. californica nAChR homology model binding sites, ␣Tyr-93 forms one of the walls deep within the binding pocket along with the side chains from , and ␥Trp-55. Based upon that structure, we would expect dTC to protect ␣Y93C from modification (but not ␣N94C, located beyond the pocket). There are potential explanations why dTC did not protect ␣Y93C from modification. First, in the structure of the binding site based upon the AChBP, inspection of the water accessible surface (Connolly surface, not shown) indicates that there is also significant accessibility to the tyrosyl side chain from outside the pocket that may provide alternative access for modification of ␣Y93C as well as ␣N94C by MTSET. Alternatively, the orientation of segment C in the nAChR binding site may be displaced from that in the model, because in the model would actually prevent dTC access to ␣Tyr-190 or ␥Trp-55 within the pocket. dTC also binds to the AChBP with high affinity , and it was noted that for dTC to have access to the aromatic pocket, the binding site would have to open up, perhaps by a movement of the ␤-hairpin ␤9-␤10 that contains segment C residues (Brejc et al., 2001) .
Although our results demonstrate clearly that ␣D200C is accessible for modification, ␣Asp-200 in our model and the equivalent amino acid in the AChBP are actually in an interior position with very little surface accessibility. The rate constant for modification of ␣D200C by MTSET is only 1% of that of ␣T196C or ␣Y198C; for modification by MBTA, however, k D200C is 10-fold higher than k Y198C . The rate constant for modification of ␣D200C by MBTA is 50-fold higher than k D200C for MTSET or MTSEA. It is possible that the structure of the AChBP predicts accurately the accessibility of ␣Asp-200 in the nAChR and that the accessibility we see for ␣D200C results from a structural perturbation caused by the substitution. However, for ␣D200C the K app for ACh is similar to wild-type, and we think it is more likely that the reactivity observed for ␣D200C is evidence that the accessibility of ␣Asp-200 is quite different than predicted from the AChBP structure and may vary in a ligand-dependent manner. Our results suggest that, in the absence of agonist, the aromatic pocket of the nAChR binding site has a more relaxed structure such that ␣D200C is accessible. This would happen if, for example, the antiparallel ␤-strands containing the segment C amino acids are further from the other elements of the binding pocket. Previous studies have provided evidence for ligand-dependent changes in the structure of the binding site. The ␣Cys-192/193 disulfide in native T. californica nAChR was readily reduced by dithiothreitol in the absence of ligands or in the presence of dTC or other antagonists, but in the presence of Ach or other full agonists, the rate constant for reduction was reduced 100-fold (Damle and Karlin, 1980) . Photolabeling patterns for [ 3 H]p-(N,N-dimethyl)aminobenzenediazonium in the resting and desensitized states of the nAChR provided evidence that in the two conformations the positions of ␣Tyr-93 and ␣Trp-149 must differ relative to the segment C residues (Galzi et al., 1991) . In addition, there is evidence that ␣Asp-200 is involved in an agonist dependent change in structure. Analysis of the functional consequences of the ␣D200N substitution in mouse nAChRs indicates that the substitution can affect the rate constant for channel opening (Akk et al., 1996) as well as the equilibrium between the resting and desensitized states (Osaka et al., 1998) .
Agonist Activation. Early studies with native nAChRs established that bromoacetylcholine acted as a covalent agonist after reduction of the ␣Cys-192/193 disulfide (Damle and Karlin, 1978; Chabala and Lester, 1986) . We established previously that covalent modification of ␣Y198C with MTSET, MTSPT, or bromoacetylcholine resulted in the addition of a covalent agonist (Sullivan and Cohen, 2000) . Reaction with either MTSET or MTSPT at other segment C residues tested resulted only in inhibition of ACh responses. Thus, interactions of the tethered trimethylammonio at a distance of ϳ7 Å from the Cys-SH of ␣Y198C can result in receptor activation, and this interaction is not accessible from other substituted cysteines within ␣195-201. This conclusion assumes that the naturally occurring disulfide bond at ␣Cys192-193 formed in the ␣Y198C mutant and that there was not aberrant disulfide bond formation leaving ␣Cys192 or ␣Cys193 as free sulfhydryls. On studies with mouse nAChR ␣Y198C, the maximal current response was potentiated 2-fold after treatment with 1 mM dithiothreitol (McLaughlin et al., 1995) , raising the possibility of aberrant disulfide bond formation that was relieved in a reducing environment. Serine substitution at ␣Y198 causes a shift of ϳ300-fold in agonist binding affinity, similar to that seen with Cys substitution (Sine et al., 1994) ; therefore, the ϳ100-fold increase in ␣Y198C K app for ACh that we observed is not itself an indicator of aberrant disulfide bond formation. Under our experimental conditions, both wild-type and ␣Y198C T. californica nAChRs showed a decrease (ϳ50%) in current response, tested at half-maximal ACh concentrations, after treatment with 1 mM dithiothreitol (data not shown), thus providing no evidence for unnatural disulfide bond formation in the ␣Y198C T. californica mutant.
In the future, it will be interesting to extend these studies in the context of this structural model. To further define the nAChR Agonist Binding Site Structure requirements necessary for receptor activation, reagents with longer tethering arms, either with additional methylenes or via tethered acylcholine itself, will be tested on residues likely to project into the pocket (␣P194, ␣T196, ␥L119). It will also be important to map the binding site surface protected by agonists, as well as by competitive antagonists smaller than dTC, and to determine the changes in accessibility and protection patterns when the binding site structure is altered allosterically by desensitizing noncompetitive antagonists.
